À retenir
In 450 adults with uncontrolled hypertension, home BP telemonitoring with pharmacist management kept routine-care readings lower for up to 24 months, but at 54 months the research-clinic systolic difference was -2.5 mm Hg (95% CI -6.3 to 1.2; P=0.18). Only 326 of 450 patients had research-clinic readings then, and the program had stopped after 12 months.
Study design
Essai randomisé
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Home blood pressure monitoring with pharmacist management had cut systolic pressure significantly while it ran, but the program stopped after 12 months and it was unknown whether the gains would last. The authors followed patients to 54 months and also compared blood pressure taken in the research clinic with readings from routine clinical care.
Population et méthode
Follow-up of a cluster randomized clinical trial in 16 primary care clinics of a large health system (March 2009 to November 2015), with 450 patients who had uncontrolled hypertension. 228 were randomized to home BP telemonitoring with pharmacist management and 222 to usual care; the intervention stopped after 12 months. The main outcome was the change in systolic and diastolic BP from baseline to 54 months, taken as the mean of 3 measurements at each research-clinic visit. Research-clinic BP was available for 326 of 450 patients (72.4%) at 54 months; routine-care BP came from 439 of 450 patients (97.6%) across 6248 visits.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1At baseline both groups averaged a systolic BP of 148 mm Hg. In the intervention group mean systolic BP was 126.7, 125.7, 126.9 and 130.6 mm Hg at 6, 12, 18 and 54 months; in usual care it was 136.9, 134.8, 133.0 and 132.6 mm Hg.
- 2By 54 months the groups had converged: the difference between groups in systolic change from baseline was -2.5 mm Hg (95% CI -6.3 to 1.2; P=0.18) and for diastolic -1.0 mm Hg (95% CI -3.2 to 1.2; P=0.37). Neither is statistically significant.
- 3Routine clinical-care measurements, which covered almost all patients, showed significantly lower systolic and diastolic BP in the intervention group for up to 24 months, which the authors read as an effect lasting 12 months after the intervention ended.
- 4Earlier results from the same trial, while the program was running, had shown larger systolic reductions in the intervention group than in usual care by -10.7, -9.7 and -6.6 mm Hg at 6, 12 and 18 months.
Limites et incertitude
- 1The 54-month research-clinic comparison is not statistically significant but its confidence interval (-6.3 to 1.2) is wide, so it cannot rule out either no lasting effect or a modest one.
- 2Research-clinic readings at 54 months came from 326 of 450 patients (72.4%), and the abstract does not say how the patients who did not attend differ from those who did.
- 3The 24-month finding rests on routine clinical measurements; the abstract does not describe how they were taken, and they were not the trial's main outcome.
- 4Patients came from 16 clinics in one health system, and the abstract does not report medication use or adherence during follow-up. This reading is based on the abstract only.
Mise en perspective
While it ran, the program clearly lowered blood pressure, and some benefit seems to have lasted for 12 months after it ended, but by 54 months the two groups looked similar. The authors' own view is that keeping control probably requires continued monitoring and restarting support if readings rise. Anyone with uncontrolled hypertension should work out monitoring and any medication changes with their clinician or pharmacist.
Vos données
This is about as close as it gets to an everyday home cuff routine: readings taken seated and rested at the same times, with weekly averages shared with your care team. The authors expect lasting control to need continued monitoring, so keep logging after support ends, and treat a rise in your average over several weeks, rather than one high reading, as the prompt to contact your clinician.
Comprendre ce type de preuve
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Importance
Hypertension is a leading cause of cardiovascular disease. The results were previously reported of a trial of home blood pressure (BP) telemonitoring and pharmacist management intervention in which the interventions stopped after 12 months. There were significantly greater reductions in systolic BP (SBP) in the intervention group than in the usual care group at 6, 12, and 18 months (-10.7, -9.7, and -6.6 mm Hg, respectively).
Objectives
To examine the durability of the intervention effect on BP through 54 months of follow-up and to compare BP measurements performed in the research clinic and in routine clinical care.
Design, setting, and participants
Follow-up of a cluster randomized clinical trial among 16 primary care clinics and 450 patients with uncontrolled hypertension in a large health system from March 2009 to November 2015.
Interventions
A home BP telemonitoring intervention with pharmacist management or usual care.
Main outcomes and measures
Change from baseline to 54 months in SBP and diastolic BP (DBP) measured as the mean of 3 measurements obtained at each research clinic visit.
Results
Among 450 patients, 228 (mean [SD] age, 62.0 [11.7] years; 54.8% male) were randomized to the telemonitoring intervention and 222 (mean [SD] age, 60.2 [12.2] years; 55.9% male) to usual care. Research clinic BP measurements were obtained from 326 of 450 (72.4%) study patients at the 54-month follow-up visit, including 162 (mean [SD] age, 62.0 [11.1] years; 54.9% male) randomized to the telemonitoring intervention and 164 (mean [SD] age, 60.0 [11.2] years; 57.3% male) to usual care. Routine clinical care BP measurements were obtained from 439 of 450 (97.6%) study patients at 6248 visits during the follow-up period. Based on research clinic measurements, baseline mean SBP was 148 mm Hg in both groups. In the intervention group, mean SBP at 6-, 12-, 18-, and 54-month follow-up was 126.7, 125.7, 126.9, and 130.6 mm Hg, respectively. In the usual care group, mean SBP at 6-, 12-, 18-, and 54-month follow-up was 136.9, 134.8, 133.0, and 132.6 mm Hg, respectively. The differential reduction by study group in SBP from baseline to 54 months was -2.5 mm Hg (95% CI, -6.3 to 1.2 mm Hg; P = .18). The DBP followed a similar pattern, with a differential reduction by study group from baseline to 54 months of -1.0 mm Hg (95% CI, -3.2 to 1.2 mm Hg; P = .37). The SBP and DBP results from routine clinical measurements suggested significantly lower BP in the intervention group for up to 24 months.
Conclusions and relevance
This intensive intervention had sustained effects for up to 24 months (12 months after the intervention ended). Long-term maintenance of BP control is likely to require continued monitoring and resumption of the intervention if BP increases.
Trial registration
ClinicalTrials.gov Identifier: NCT00781365.
Sources et attribution
Long-term Outcomes of the Effects of Home Blood Pressure Telemonitoring and Pharmacist Management on Blood Pressure Among Adults With Uncontrolled Hypertension: Follow-up of a Cluster Randomized Clinical Trial.
Margolis KL, Asche SE, Dehmer SP, Bergdall AR, Green BB, Sperl-Hillen JM, Nyboer RA, Pawloski PA, Maciosek MV, Trower NK, O'Connor PJ.
JAMA network open · 2018-09-07
DOI: 10.1001/jamanetworkopen.2018.1617 ↗PubMed · 30646139 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people
Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.
Journal of the American Heart Association
Five exercise types lowered resting blood pressure, isometric training the most
Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.
British Journal of Sports Medicine
A salt substitute lowered stroke, major cardiovascular events and death in rural China
In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.
The New England Journal of Medicine
Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation
Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.
The New England Journal of Medicine

